Clinical Trial: A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets

U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06972498) titled 'A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets' on May 04.

Brief Summary: The population receiving ivosimab combined with chemotherapy for neoadjuvant treatment of colorectal cancer liver metastasis.

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Colorectal Cancer With Liver Metastasis

Intervention: DRUG: Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.

Patients will receive ivosimab combined with the X...